We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+4.24%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.94B
AUM Growth
-$224M
Cap. Flow
-$1.92B
Cap. Flow %
-24.14%
Top 10 Hldgs %
74.98%
Holding
115
New
11
Increased
21
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$30.4M
2
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$19.4M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$16.5M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$15.8M
5
XNPT
XENOPORT, INC.
XNPT
+$13.6M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$209M
2
QCOR
QUESTCOR PHARMA INC
QCOR
+$46.2M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$32.8M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.1M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 44.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$1.13B 14.28%
9,656,599
+65,053
+0.7% +$7.41M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$836M 10.52%
22,475,729
+3,500
+0% +$138K
GEVA
3
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$733M 9.23%
10,660,432
– –
INCY icon
4
Incyte
INCY
$25.9B
$728M 9.17%
14,845,559
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$5.08B
$507M 6.39%
20,481,442
– –
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$387M 4.87%
13,655,618
+716
+0% +$20K
AVNR
7
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$250M 3.15%
20,974,677
+2,416,190
+13% +$16.5M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12.9B
$171M 2.15%
2,370,464
+462,234
+24% +$30.4M
AVNR
9
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$112M 1.4%
+9,356,200
New +$63.9M
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.44B
$105M 1.32%
10,713,686
-177,186
-2% -$2.17M
ANAC
11
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$103M 1.3%
4,204,702
+956,659
+29% +$19.4M
XOMA
12
DELISTED
Xoma
XOMA
$97.1M 1.22%
1,153,574
+275
+0% +$23.5K
DYAX
13
DELISTED
DYAX CORPORATION
DYAX
$62.3M 0.78%
6,157,789
+476,552
+8% +$4.62M
CERS icon
14
Cerus
CERS
$566M
$47.9M 0.6%
11,940,178
+1,693,587
+17% +$6.51M
VNDA icon
15
Vanda Pharmaceuticals
VNDA
$319M
$45.4M 0.57%
4,372,153
– –
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$41.7M 0.52%
2,380,074
– –
XNPT
17
DELISTED
XENOPORT, INC.
XNPT
$36.7M 0.46%
6,815,777
+2,781,665
+69% +$13.6M
DSCI
18
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$29.5M 0.37%
3,537,137
– –
RPRX
19
DELISTED
Repros Therapeutics Inc.
RPRX
$27.5M 0.35%
2,778,654
– –
GILD icon
20
Gilead Sciences
GILD
$181B
$27.3M 0.34%
256,108
– –
ACOR
21
DELISTED
Acorda Therapeutics
ACOR
$25.5M 0.32%
6,278
-1,273
-17% -$4.78M
HALO icon
22
Halozyme
HALO
$12.3B
$25.3M 0.32%
2,776,143
– –
ARAV
23
DELISTED
Aravive, Inc. Common Stock
ARAV
$23.7M 0.3%
207,682
+34
+0% +$4.5K
PGNX
24
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$23.1M 0.29%
4,449,797
– –
CPRX
25
DELISTED
Catalyst Pharmaceutical
CPRX
$22.3M 0.28%
6,715,462
+4,492,409
+202% +$11.7M
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2014 Portfolio in Review

As of Q3 2014, Julian Baker held 115 positions worth $7.94B, down 2.7% from $8.16B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Julian Baker withdrew a net $1.92B in Q3 2014, closing 7 positions and reducing 12 holdings. Its most notable exit was INTERMUNE INC, an estimated $209M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 45% a quarter earlier.

Against the trend, Julian Baker opened a new position in MALLINCKRODT PUBLIC LIMITED COMPANY worth $18.2M.

  • Julian Baker's largest Q3 2014 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 201,856 shares worth $18.2M.
  • Julian Baker added most to BioMarin Pharmaceuticals in Q3 2014, an estimated $30.4M increase.
  • Julian Baker's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $18.1M.
  • Julian Baker fully exited INTERMUNE INC in Q3 2014, selling an estimated $209M.
  • Julian Baker's ten largest holdings make up 75% of its $7.94B portfolio in Q3 2014.
  • Julian Baker opened 11 new positions and closed 7 in Q3 2014.
  • Julian Baker's portfolio value fell 2.7% quarter-over-quarter to $7.94B.

Based on Baker Bros. Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.